Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Dec 14, 2023 8:01am

652 Views

Post# 35783944

A Conversation With Antibe Therapeutics

15 Prince Arthur Ave.
Toronto, ON, Canada, M5R 1B2
TSX:ATE OTCQX:ATBPF
antibethera.com

A Conversation With Antibe Therapeutics

Thursday, January 18, 2024 @ 11 am EST

Join us for A Conversation with Antibe Therapeutics... learn about the benefits of otenaproxesul's new formulation, dive into Antibe's recently released data and Phase II planning, and explore the future of pain management.

As the opioid crisis drives prescribers, patients, payors and policymakers toward non-addictive alternatives, nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed to treat acute pain. However, today's NSAIDs can cause gastrointestinal ulcers and bleeding, especially at the higher doses often employed in acute indications. Formulated to promote rapid onset of action, otenaproxesul is a non-opioid oral painkiller Its Phase II trial is set to initiate in calendar Q1 2024, with top-line data expected in Q3 2024. With no novel oral pain drugs introduced since the late 1990s, there is urgent demand for alternatives to opioids to treat post-operative pain, acute musculoskeletal pain, dental pain and a range of other acute pain indications.

Dr. Bhargava of Allele Capital will join Dan Legault, Chief Executive Officer of Antibe Therapeutics, and Dr. Joe Stauffer, the company's Chief Medical Officer. Tune in as they share insights on otenaproxesul’s transformative potential in acute pain management.

DAN LEGAULT, JD Trained as a corporate lawyer and as an air force rescue pilot, Dan has since focused on high-growth technology-based companies. His CEO-level experience includes organizations specializing in data analytics, IT and consumer marketing.
Dan has served on the boards of directors of International Save the Children and of Green Shield Canada, a leading health benefits administrator. He continues to serve as a board member and advisor to several companies and not-for-profit organizations.

JOSEPH STAUFFER, DO, MBA, FAPCR Following his medical training, Joe practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (FDA) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director.
Over the succeeding years, Joe led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions. He was also instrumental in guiding the clinical development programs that underpinned equity raises totaling more than $250 million for Cara Therapeutics, a developer of novel chemical entities to treat post-operative pain and a form of chronic itch.

ANKIT BHARGAVA, MD (Moderator)
Dr. Bhargava carries with him over eight years of progressively senior positions in strategy, due diligence, and advisory in the life sciences industry. Prior to joining Allele Capital, he was a Manager at Pointe Advisory, where he advised some of the top pharmaceutical companies as well as large-cap biotech in oncology and rare diseases. Prior to Pointe, Dr. Bhargava was the Chief Strategy Officer of Canadian-based start-up Ana Health, a women’s health-based company, and the Founder of a home health company.

Dr. Bhargava was a resident physician at Eastern Virginia Medical School and conducted his postdoctoral research at the University of Chicago related to the oncological repercussions of inflammatory bowel disease treatment. He earned his Doctorate of Medicine at the University of Windsor School of Medicine, where he finished basic science coursework at the top of his class. He also holds a Bachelor of Science in Biology from Indiana University.